Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Aetna picks Gilead’s hepatitis C drugs

Health insurance firm favours Sovaldi and Harvoni after negotiating discount

ABPI London offices

ABPI: Put value-based assessment back on the agenda

Industry body wants stalled project to be revived in a broad context that would include NICE reform

- PMLiVE

Boehringer drug approved in EU for rare lung disease

Nintedanib is already available as cancer treatment

- PMLiVE

RCGP animation to improve patient care

Encourages doctors to consider a holistic approach to care planning

- PMLiVE

Novo Nordisk’s Xultophy debuts in Switzerland

It is the first market for combination of diabetes treatments Tresiba and Victoza

Roche Basel Switzerland

Roche buys rare disease firm Trophos in €470m deal

Will take control of olesoxime for spinal muscular atrophy

- PMLiVE

A baptism of fire for Europe’s new health commissioner

Controversial trade deals, the spread of Ebola and the threat of austerity are just three of the issues facing Dr Vytenis Andriukaitis

- PMLiVE

MedDay appoints former Sanofi VP to board

Philippe Goupit joins French biotech

- PMLiVE

Janssen will cover cost of unsuccessful hepatitis C treatment

NHS England will only have to pay for Olysio if patient clears virus

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

- PMLiVE

EC clears AbbVie’s oral hepatitis C regimen

Viekirax and Exviera offer competition to Gilead’s Sovaldi

- PMLiVE

Clinical data sharing ‘should be the norm’, says IoM

US Institute pitches into clinical data transparency debate

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links